Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Arcus Biosciences (RCUS)

Arcus Biosciences estimates $694.0 million cash and securities at September 30, 2026

Neutral Impact 3 of 5 earnings

Arcus Biosciences disclosed a preliminary estimate of about $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026. The figure is unaudited, subject to financial closing procedures, and Ernst & Young has not reviewed it, so it may change. The filing contains no revenue, profit or guidance figures, so it gives shareholders a liquidity snapshot rather than full results.

Key points

  • Preliminary cash, cash equivalents and marketable securities: approximately $694.0 million as of September 30, 2026
  • Figure is unaudited and subject to completion of financial closing procedures and management review
  • Ernst & Young LLP has not audited or reviewed the preliminary data
  • Filing does not include revenue, net income, EPS or guidance

The filing

CompanyArcus Biosciences (RCUS)
Form8-K, current report
Filed with the SECOct 21, 2026, 4:09 PM ET
Accession number0001193125-26-427829

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:17 PM ET, from the text of the filing and its press-release exhibits only.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.